The Issue Price represents a discount of approximately 12.0% from the closing price of the Common Shares on the TSX Venture Exchange on Friday, July 4, 2025. The Corporation anticipates using the net proceeds of the Offering for working capital and general corporate purposes.
The Offering will be made by way of a prospectus supplement (the "Prospectus Supplement") to the short form base shelf prospectus of the Corporation dated September 6, 2024, which Prospectus Supplement will be prepared and filed by the Corporation prior to the closing of the Offering with the securities regulatory authorities in each of the provinces and territories of Canada, as well as with the U.S. Securities and Exchange Commission as part of the Corporation's U.S. registration statement on Form F-10 ("Form F-10") (Registration No. 333-280553) under the U.S.-Canada Multijurisdictional Disclosure System, with such additions thereto and deletions therefrom as may be permitted or required by Form F-10. The Offering is expected to be fully subscribed by a single institutional investor in Canada that qualifies as an "accredited investor" under National Instrument 45-106, Prospectus Exemptions of the Canadian Securities Administrators.
The consummation of the Offering remains subject to the receipt of all regulatory approvals, including the approval of the TSX Venture Exchange (the "Exchange"), and the satisfaction of other customary closing conditions. No commission or finder's fee will be paid in connection with the Offering.
"We are very fortunate to have had strong interest from institutional, strategic and public market investors over the past 15 months, ...
